GAIN THERAPEUTICS INC (GANX) Stock Price, Quote, News and Overview
NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD
GANX Quote, Performance and Key Statistics
1.77
-0.02 (-1.12%)
The current stock price of GANX is 1.77 USD. In the past month the price decreased by -2.21%. In the past year, price increased by 37.21%.
GANX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.31B | ||
| AMGN | AMGEN INC | 13.94 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
| ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 18.70B | ||
| BIIB | BIOGEN INC | 8.03 | 18.62B |
Related stock screener links
About GANX
Company Profile
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Company Info
GAIN THERAPEUTICS INC
4800 Montgomery Lane, Suite 220
Bethesda MARYLAND 20814 US
CEO: Eric Richman
Employees: 31
Phone: 13015001556
GAIN THERAPEUTICS INC / GANX FAQ
What is the stock price of GAIN THERAPEUTICS INC today?
The current stock price of GANX is 1.77 USD. The price decreased by -1.12% in the last trading session.
What is the ticker symbol for GAIN THERAPEUTICS INC stock?
The exchange symbol of GAIN THERAPEUTICS INC is GANX and it is listed on the Nasdaq exchange.
On which exchange is GANX stock listed?
GANX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GAIN THERAPEUTICS INC stock?
13 analysts have analysed GANX and the average price target is 8.16 USD. This implies a price increase of 361.02% is expected in the next year compared to the current price of 1.77. Check the GAIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GAIN THERAPEUTICS INC worth?
GAIN THERAPEUTICS INC (GANX) has a market capitalization of 52.32M USD. This makes GANX a Micro Cap stock.
How many employees does GAIN THERAPEUTICS INC have?
GAIN THERAPEUTICS INC (GANX) currently has 31 employees.
What are the support and resistance levels for GAIN THERAPEUTICS INC (GANX) stock?
GAIN THERAPEUTICS INC (GANX) has a support level at 1.72 and a resistance level at 1.86. Check the full technical report for a detailed analysis of GANX support and resistance levels.
Should I buy GAIN THERAPEUTICS INC (GANX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GANX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GANX, evaluating the profitability, health, valuation and growth aspects
- GAIN THERAPEUTICS INC (GANX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GAIN THERAPEUTICS INC (GANX) Sales and EPS estimates to see what analysts future expectations are.
- GAIN THERAPEUTICS INC (GANX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GAIN THERAPEUTICS INC (GANX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GAIN THERAPEUTICS INC (GANX) Stock Chart to make your own analysis
- GAIN THERAPEUTICS INC (GANX) Latest news and press-releases to stay up to date.
Does GAIN THERAPEUTICS INC (GANX) stock pay dividends?
GANX does not pay a dividend.
When does GAIN THERAPEUTICS INC (GANX) report earnings?
GAIN THERAPEUTICS INC (GANX) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of GAIN THERAPEUTICS INC (GANX)?
GAIN THERAPEUTICS INC (GANX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.86).
What is the Short Interest ratio of GAIN THERAPEUTICS INC (GANX) stock?
The outstanding short interest for GAIN THERAPEUTICS INC (GANX) is 1.03% of its float. Check the ownership tab for more information on the GANX short interest.
GANX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GANX. When comparing the yearly performance of all stocks, GANX turns out to be only a medium performer in the overall market: it outperformed 66.34% of all stocks.
GANX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GANX. GANX has a bad profitability rating. Also its financial health evaluation is rather negative.
GANX Financial Highlights
Over the last trailing twelve months GANX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 45.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.36% | ||
| ROE | -278.1% | ||
| Debt/Equity | 0.04 |
GANX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to GANX. The Buy consensus is the average rating of analysts ratings from 13 analysts.